Head to head
Albemarle vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: ALB · LIN
ALB
Albemarle
102.75-3.38%
1-year price shape — +15% over the period
Quant Rating D · 54/100
vs
LIN
Linde
483.98-1.22%
1-year price shape — +4% over the period
Quant Rating D · 45/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde trades cheapest on trailing earnings; Linde earns the most per share.
| ALB | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | Specialty Chemicals | Specialty Chemicals |
| Last price | 102.75 | 483.98 |
| Change today | -3.38% | -1.22% |
| 1-year return | +14.8% | +4.3% |
| Market cap | $12.13B | $223.11B |
| 52-week range | 87.01 – 219.70 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | 380.56 | 31.22 |
| P/E percentile, own 5-yr range | 97th | 8th |
| P/B | 1.51 | 5.71 |
| Dividend yield | 1.58% | 1.28% |
| Profitability & growth | ||
| EPS (TTM) | -5.76 | 14.61 |
| Net profit (TTM) | $-679.71M | $6.73B |
| Revenue (TTM) | $5.91B | $35.45B |
| Revenue growth (YoY) | +31.1% | +9.3% |
| Gross margin | 23.8% | 48.3% |
| Operating margin | 13.7% | 27.1% |
| Net margin | 1.0% | 20.4% |
| Free cash flow (TTM) | $1.34B | $4.98B |
| Ownership & sentiment | ||
| Institutional ownership | 99.5% | 88.0% |
| Insider activity (12mo) | 39 buy / 11 sell | 33 buy / 13 sell |
| Short interest (% of float) | 9.4% | 1.3% |
| Analyst consensus | 75% buy / 25% hold (12) | 87% buy / 13% hold (15) |
| Analyst price target | $177 (+73%) | $557 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (54) | D (45) |
| Company | ||
| Employees | 7,800 | 65,177 |
| Founded | 1993 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.